A Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-14

Study Completion Date

2024-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the safety and feasibility of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

InTRaoperative Imaging DEvice Based on endogeNous opTical Properties to Evaluate Bowel Oxygenation in Colorectal Resections

NCT05973227

Left-sided Colorectal Resection : Diverticular Diseases Left-sided Colorectal Resection : Colonic Neoplasms Left-sided Colorectal Resection : Rectal Neoplasms

COMPLETED NA

NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome

NCT02570516

Lynch Syndrome

COMPLETED NA

Feasibility Study of a Novel Single Use Robotic Colonoscopy System

NCT03979690

Colonic Polyp Colon Adenoma Colorectal Cancer

COMPLETED NA

Exploratory Study of Upper and Lower Endoscopic Fuse System

NCT02651857

Gastrointestinal Diseases

COMPLETED NA

NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours

NCT04761172

GIST

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Injury to the ureter, the duct by which urine passes from the kidney into the bladder, is a well-known and serious complication of pelvic and abdominal surgery that frequently goes unrecognized intraoperatively. This study seeks to evaluate the safety and feasibility of intravenous IS-001 injection to improve surgeon ureter visualization during robotic-assisted surgery with the da Vinci® Surgical System and Firefly® imaging.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ureter Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Single Arm Safety and Feasibility Study of IS-001 with 20 mg in Multiple Injections

Group Type EXPERIMENTAL

IS-001

Intervention Type DRUG

Intravenous injection of IS-001 investigational drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IS-001

Intravenous injection of IS-001 investigational drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects between the ages of 18 and 75, inclusive
2. Subject is scheduled to undergo robotic-assisted rectal, sigmoid, or left colon resection surgery using the da Vinci® X/Xi Surgical System with Firefly® Fluorescent Imaging

Exclusion Criteria

1. Subject is pregnant or nursing
2. Subject has known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
3. Subject has any of the following screening laboratory values:

1. eGFR \< 60 mL/min/1.73 m\^2
2. Aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase ≥ 2.5 × ULN
3. Alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase ≥ 2.5 × ULN
4. Subject is already enrolled in another investigational drug or device study receiving therapeutic agents within the past 6 months
5. Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data or represents an unacceptable safety profile
6. Subjects with known or suspected hypersensitivity to indocyanine green (ICG) or any components of the formulation used.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No